Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects. ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyt ...

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

It seems like not a day goes by without billionaire Elon Musk making headlines. The boss of X (formerly Twitter), Tesla and SpaceX is the world's richest person and has used his platform to make ...

Duoning Biotech enters partnership with Branca Bunús to promote the next generation of transfection reagents: Shanghai Thursday, November 7, 2024, 16:00 Hrs [IST] Duoning Biotech ...

MaxCyte now expects full year 2024 core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year ...

Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agreement, the two companies will collaborate on the development ...

Discover methods for accurate DNA and RNA quantification and learn how to analyze purity and concentration to enhance ...

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.